Cefa-Lak Uses, Dosage, Side Effects and more
Cefa-Lak (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in the United States. Cefa-Lak is partly plasma-bound and is effective against gram-negative and gram-positive organisms.
Cephapirin is a first-generation cephalosporin that has a wide spectrum of activity against gram-positive and gram-negative organisms. Cephapirin is more resistant to beta-lactamases than are the penicillins and so is effective against staphylococci, with the exception of methicillin-resistant staphylococci.
| Trade Name | Cefa-Lak |
| Generic | Cefapirin |
| Cefapirin Other Names | Cefapirin, Cefapirina, Cefapirine, Cefapirinum, Cefaprin, Cephapirin, Cephapirine |
| Type | |
| Formula | C17H17N3O6S2 |
| Weight | Average: 423.463 Monoisotopic: 423.055876671 |
| Groups | Approved, Vet approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | USA |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Cefa-Lak is a first generation cephalosporin indicated in the treatment of susceptible bacterial infections.
For treatment of infections caused by susceptible bacteria.
Cefa-Lak is also used to associated treatment for these conditions: Bronchitis, Pharyngitis, Respiratory Tract Infections (RTI), Skin and Soft Tissue Infections, Tonsillitis, Urinary Tract Infection
How Cefa-Lak works
The bactericidal activity of cephapirin results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).
Toxicity
Rats exposed via the oral route to cephapirin displayed low acute toxicity (LD50 = 14000 mg/kg). The most common adverse reactions are hypersensitivity reactions and alterations to liver function. Evidence of white blood cell disorders and anaemia were noted in some subjects.
